Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Immunovant, Inc. - Common Stock (NQ:IMVT)

26.57 +1.15 (+4.52%)
Streaming Delayed Price Updated: 10:58 AM EST, Jan 2, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Immunovant, Inc. - Common Stock

News headline image
IMMUNOVANT INVESTIGATION INITIATED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Immunovant, Inc. - IMVT
From Kahn Swick & Foti, LLC
Via GlobeNewswire
News headline image
IMMUNOVANT INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Immunovant, Inc. - IMVT
From Kahn Swick & Foti, LLC
Via Business Wire
News headline image
IMVT Investors Have Opportunity to Join Immunovant, Inc. Fraud Investigation with the Schall Law Firm
From The Schall Law Firm
Via Business Wire
Immunovant Inc. (NASDAQ: IMVT) Records 52-Week High Tuesday Morning
Via Investor Brand Network
News headline image
IMMUNOVANT INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Immunovant, Inc. - IMVT
From Kahn Swick & Foti, LLC
Via Business Wire
News headline image
IMVT INVESTIGATION ALERT: Pittsburgh Law Office of Alfred G. Yates Jr. PC Announces Investigation into a Private Placement Transaction by Immunovant, Inc. and Encourages Investors to Contact the Firm
Via ACCESS Newswire
News headline image
IMVT INVESTIGATION ALERT: Robbins Geller Rudman & Dowd LLP Announces Investigation into a Private Placement Transaction by Immunovant, Inc. and Encourages Investors to Contact the Firm
From Robbins Geller Rudman & Dowd LLP
Via Business Wire
Immunovant Inc. (NASDAQ: IMVT) is a Stock Spotlight on 5/23
Via Investor Brand Network
Immunovant Inc. (NASDAQ: IMVT) is a Stock Spotlight on 3/24
Via Investor Brand Network
News headline image
Immunovant Announces Next Phase of Growth with Roivant Including Changes to its Leadership Team and Additional Indications Sjögren’s Disease (SjD) and Cutaneous Lupus Erythematosus (CLE) for IMVT-1402
From Roivant Sciences
Via GlobeNewswire
News headline image
Roivant Provides Update on Graves’ Disease Development Program
From Roivant Sciences
Via GlobeNewswire
News headline image
Roivant Reports Positive Initial Phase 2 Results for Batoclimab in Graves’ Disease
From Roivant Sciences
Via GlobeNewswire
News headline image
Roivant Announces Positive IMVT-1402 Initial 600 mg MAD Results that Confirm Best-in-Class Potential
From Roivant Sciences
Via GlobeNewswire
News headline image
Immunovant to Present at Guggenheim 4th Annual Immunology and Neurology Day on November 14th
From Immunovant Inc.
Via GlobeNewswire
News headline image
Immunovant Reports Financial Results and Recent Business Updates for the Quarter Ended September 30, 2022
From Immunovant Inc.
Via GlobeNewswire
R&D Efforts to Improve Optimal Treatments for Advanced Pancreatic Ductal Adenocarcinoma (PDAC) Progressing
Palm Beach, FL – October 5, 2022 – FinancialNewsMedia.com News Commentary – Advanced pancreatic ductal adenocarcinoma (PDAC) remains a significant cause of mortality accounting for up to 4% of all... 
Via FinancialNewsMedia
Topics Death
News headline image
NASDAQ:IMVT Long Term Shareholder Notice: Investigation over Possible Wrongdoing at Immunovant, Inc. ↗
San Diego, CA -- (SBWIRE) -- 05/19/2021 -- An investigation was announced concerning potential breaches of fiduciary duties by certain directors of Immunovant, Inc. 
Via SBWire
Topics Lawsuit
News headline image
DEADLINE TOMORROW: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against Immunovant, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Lawsuit
News headline image
TUESDAY DEADLINE NOTICE: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against Immunovant, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Lawsuit
News headline image
TUESDAY DEADLINE REMINDER: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against Immunovant, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Lawsuit
News headline image
The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Immunovant, Inc. f/k/a Health Sciences Acquisitions Corporation (IMVT)
From The Law Offices of Frank R. Cruz
Via Business Wire
News headline image
TUESDAY DEADLINE ALERT: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against Immunovant, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Lawsuit
News headline image
7-DAY DEADLINE ALERT: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against Immunovant, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Lawsuit
News headline image
UPCOMING DEADLINE NOTICE: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against Immunovant, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Lawsuit
News headline image
NASDAQ:IMVT Investor Notice: Deadline on April 20, 2021 in Lawsuit Against Immunovant, Inc. ↗
San Diego, CA -- (SBWIRE) -- 04/07/2021 -- A deadline is coming up on April 20, 2021 in the lawsuit filed for certain investors of Immunovant, Inc. (NASDAQ:IMVT). 
Via SBWire
Topics Lawsuit
News headline image
UPCOMING DEADLINE REMINDER: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against Immunovant, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Lawsuit
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.